ciglitazone has been researched along with Airway Hyper-Responsiveness in 3 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rhee, CK | 1 |
| Lee, SY | 1 |
| Kang, JY | 1 |
| Kim, SJ | 1 |
| Kwon, SS | 1 |
| Kim, YK | 1 |
| Park, SH | 1 |
| Woerly, G | 1 |
| Honda, K | 1 |
| Loyens, M | 1 |
| Papin, JP | 1 |
| Auwerx, J | 1 |
| Staels, B | 1 |
| Capron, M | 1 |
| Dombrowicz, D | 1 |
| Ward, JE | 1 |
| Fernandes, DJ | 1 |
| Taylor, CC | 1 |
| Bonacci, JV | 1 |
| Quan, L | 1 |
| Stewart, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity[NCT00614874] | Phase 2 | 16 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | parts per billion (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Rosiglitazone | 48 | 41 |
FEV1 in liters (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | Liters (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 2.95 | 3.04 |
Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | percent predicted (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 82 | 85 |
PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20% (NCT00614874)
Timeframe: patients were assessed at baseline and at 12 weeks
| Intervention | mg/mL (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 3.27 | 8.71 |
3 other studies available for ciglitazone and Airway Hyper-Responsiveness
| Article | Year |
|---|---|
Effect of peroxisome proliferator-activated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma.
Topics: Administration, Intranasal; Animals; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchial Provocation T | 2009 |
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation.
Topics: Anilides; Animals; Asthma; Chemotaxis; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation | 2003 |
The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.
Topics: Allergens; Animals; Bronchoalveolar Lavage Fluid; Bronchoconstrictor Agents; Disease Models, Animal; | 2006 |